Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease (ILD) of unknown aetiology, with a median survival of 2–4 years from the time of …

The complexity of neoplasia and its treatment are a challenge to the formulation of general
criteria that are applicable across solid cancers. Determining the number of prior lines of …

Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …

Introduction Acquired resistance to TKI is an important unmet need in the management of
EGFR mutated lung cancer. Recent clinical trial IMPower150 suggested that combination …

Glioblastoma multiforme (GBM) is the most common and invasive primary central nervous
system tumor in humans, accounting for approximately 45–50% of all primary brain tumors …

Background Acquired resistance development is a major challenge in the epidermal growth
factor receptor‐tyrosine kinase inhibitor (EGFR–TKI) treatment of non–small cell lung cancer …

Background This study aimed to conduct a systematic review of the literature to identify key
randomized controlled clinical trials (RCTs), followed by network meta-analysis, to compare …

Background Osimertinib monotherapy is a common treatment for epidermal growth factor
receptor (EGFR)-mutant non-small cell lung cancer (NSCLC); however, standard treatment …

Background: The exosome-focused translational research for afatinib (EXTRA) study is the
first trial to identify novel predictive biomarkers for longer treatment efficacy of afatinib in …

Lung cancer is the leading cause of cancer-related deaths with high morbidity and mortality.
Non–small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting …